Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
2024

Tezepelumab for Severe Asthma

Sample size: 1059 publication 10 minutes Evidence: high

Author Information

Author(s): Wechsler Michael E., Brusselle Guy, Virchow J. Christian, Bourdin Arnaud, Kostikas Konstantinos, Llanos Jean-Pierre, Roseti Stephanie L., Ambrose Christopher S., Hunter Gillian, Jackson David J., Castro Mario, Lugogo Njira, Pavord Ian D., Martin Neil, Brightling Christopher E.

Primary Institution: National Jewish Health, Denver, CO, USA

Hypothesis

Tezepelumab treatment improves clinical response and remission in patients with severe, uncontrolled asthma.

Conclusion

Tezepelumab treatment significantly increases the likelihood of achieving clinical response and remission in patients with severe asthma compared to placebo.

Supporting Evidence

  • 46% of tezepelumab recipients achieved complete clinical response compared to 24% of placebo recipients.
  • 28.5% of tezepelumab recipients achieved on-treatment clinical remission over the first year.
  • 33.5% of tezepelumab recipients achieved on-treatment clinical remission over the second year.

Takeaway

Tezepelumab helps people with severe asthma feel better and stay better for a longer time compared to those who don't take it.

Methodology

The study involved two phase 3, randomized, double-blind, placebo-controlled trials assessing tezepelumab's effects on clinical response and remission in patients with severe asthma.

Potential Biases

Potential bias due to missing data and the influence of the pandemic on patient outcomes.

Limitations

The study's findings may be influenced by the COVID-19 pandemic, which affected data collection and exacerbation rates.

Participant Demographics

Patients aged 12-80 years with severe, uncontrolled asthma, including those with varying blood eosinophil counts.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 2.10–3.82

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1183/13993003.00316-2024

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication